Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 625,143
  • Shares Outstanding, K 54,550
  • Annual Sales, $ 227,190 K
  • Annual Income, $ 115,550 K
  • 60-Month Beta 0.48
  • Price/Sales 2.76
  • Price/Cash Flow 5.31
  • Price/Book 1.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.09
  • Number of Estimates 2
  • High Estimate 0.11
  • Low Estimate 0.08
  • Prior Year 0.21
  • Growth Rate Est. (year over year) -57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.57 +8.39%
on 05/07/20
12.21 -6.14%
on 05/12/20
-0.29 (-2.47%)
since 05/05/20
3-Month
7.12 +60.96%
on 03/18/20
12.33 -7.06%
on 04/27/20
+0.37 (+3.34%)
since 03/05/20
52-Week
7.12 +60.96%
on 03/18/20
17.85 -35.80%
on 12/09/19
-3.33 (-22.52%)
since 06/05/19

Most Recent Stories

More News
Vanda Pharmaceut Falls 2.16% on Heavy Volume: Watch For Potential Rebound

Vanda Pharmaceut (NASDAQ:VNDA) traded in a range yesterday that spanned from a low of $10.83 to a high of $11.21. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of...

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format...

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the...

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from , M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data...

VNDA : 11.46 (-0.17%)
Vanda Pharmaceut (VNDA)

SmarTrend identified a Downtrend for Vanda Pharmaceut (NASDAQ:VNDA) on April 2nd, 2020 at $10.30. In approximately 2 months, Vanda Pharmaceut has returned 13.65% as of today's recent price of $11.70.

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on , it has reached...

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 11.46 (-0.17%)
Vanda: 1Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported first-quarter net income of $486,000, after reporting a loss in the same period a year earlier.

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ) today announced financial and operational results for the first quarter ended .

VNDA : 11.46 (-0.17%)
Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020

, /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2020 on , after the market closes.  

VNDA : 11.46 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade VNDA with:

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

2nd Resistance Point 12.12
1st Resistance Point 11.79
Last Price 11.46
1st Support Level 11.28
2nd Support Level 11.10

See More

52-Week High 17.85
Fibonacci 61.8% 13.75
Fibonacci 50% 12.49
Last Price 11.46
Fibonacci 38.2% 11.22
52-Week Low 7.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar